Vimseltinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

About Vimseltinib

Vimseltinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2025. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors and Organic Cation Transporter 2 Inhibitors. DrugCentral lists 6 molecular targets, including CSF1R, KIT and PDGFRA. Recorded indications include Allan-Hernon-Dudley syndrome.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Allan-Hernon-Dudley syndrome

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors; Organic Cation Transporter 2 Inhibitors; P-Glycoprotein Inhibitors
• Established pharmacologic class: Kinase Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Macrophage colony-stimulating factor 1 receptor	CSF1R	inhibitor	Kd 8.64
Mast/stem cell growth factor receptor Kit	KIT	inhibitor	IC50 7.00
Platelet-derived growth factor receptor alpha	PDGFRA	unknown	IC50 6.36
Protein-tyrosine kinase 6	PTK6	unknown	IC50 5.68
Platelet-derived growth factor receptor beta	PDGFRB	unknown	IC50 5.64
Tyrosine-protein kinase Lck	LCK	unknown	IC50 5.55

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2025-09-17	EMA	—	Deciphera Pharmaceuticals (Netherlands) B.V.	Yes
2025-02-14	FDA	—	Deciphera Pharmaceuticals

ATC classification

ATC code	Therapeutic hierarchy
L01EX29	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vimseltinib is on its molecule page.

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: TVGAHWWPABTBCX-UHFFFAOYSA-N
• PubChem CID: 86267612

CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C

Sources & how this page is made

This page is compiled automatically from public scientific databases and is refreshed when those sources are re-ingested. It is not written or reviewed by a clinician.

• DrugCentral — structures, indications, targets, approvals (CC BY-SA 4.0)
• FDA Orange Book — patents and exclusivity
• FDA Adverse Event Reporting System (FAERS) — adverse-event signals
• PharmGKB / CPIC — pharmacogenomics
• PubChem — chemical identifiers